Research ArticleArticle
Are Capecitabine and the Active Metabolite 5-FU CNS Penetrable to Treat Breast Cancer Brain Metastasis?
Jinqiang Zhang, Lingli Zhang, Yumei Yan, Shaorong Li, Liang Xie, Wei Zhong, Jing Lv, Xiuhua Zhang, Yu Bai and Ziqiang Cheng
Drug Metabolism and Disposition March 2015, 43 (3) 411-417; DOI: https://doi.org/10.1124/dmd.114.061820
Jinqiang Zhang
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
Lingli Zhang
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
Yumei Yan
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
Shaorong Li
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
Liang Xie
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
Wei Zhong
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
Jing Lv
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
Xiuhua Zhang
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
Yu Bai
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
Ziqiang Cheng
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
CNS Penetration of 5-FU to Treat Breast Cancer Brain Metastasis
Jinqiang Zhang, Lingli Zhang, Yumei Yan, Shaorong Li, Liang Xie, Wei Zhong, Jing Lv, Xiuhua Zhang, Yu Bai and Ziqiang Cheng
Drug Metabolism and Disposition March 1, 2015, 43 (3) 411-417; DOI: https://doi.org/10.1124/dmd.114.061820
Research ArticleArticle
CNS Penetration of 5-FU to Treat Breast Cancer Brain Metastasis
Jinqiang Zhang, Lingli Zhang, Yumei Yan, Shaorong Li, Liang Xie, Wei Zhong, Jing Lv, Xiuhua Zhang, Yu Bai and Ziqiang Cheng
Drug Metabolism and Disposition March 1, 2015, 43 (3) 411-417; DOI: https://doi.org/10.1124/dmd.114.061820
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement